Evidence from genetic, transgenic and post-mortem studies has strongly supported the critical role that neuregulin 1 (NRG1) and its ErbB4 receptor plays in the pathophysiology of schizophrenia. This article aims to review current evidence regarding the effects of antipsychotic treatment on NRG1-ErbB4 signalling. NRG1 and ErbB4 knockout mice display abnormal behaviours relevant to certain features of schizophrenia, which could be improved by antipsychotic (clozapine/haloperidol) treatment. In contrast to most NRG1/ErbB4 knockout mice with a decreased NRG1-ErbB4 signalling, the majority post-mortem studies showed an increased NRG1-ErbB4 signalling in schizophrenic patients. These differences could be due to degrees of alteration in risk genes (subtle variations in patients vs pronounced alteration in mutant mice) or the duration of the modification on NRG1 signalling. Various antipsychotics have different effects on NRG1 and ErbB4 expression and signalling that are dependent on treatment duration. Current evidence suggests that a chronic (12 weeks) antipsychotic treatment, at least in animal models, could downregulate NRG1-ErbB4 signalling, although an upregulation is seen for a short-term treatment. These effects may be due to multiple binding profiles with various G-coupled protein receptors (e.g. dopamine, and serotonin receptors) of antipsychotics. Studies are needed to investigate the interactions between NRG1-ErbB4 and the other signalling pathways (such as glutamatergic, GABAergic and dopaminergic). Furthermore, the interactions between NRG1/ErbB4 and other schizophrenia suspensibility genes under antipsychotic treatment also require investigation.
Introduction
Although the aetiology and pathophysiology of schizophrenia are still not fully understood, it has been widely accepted that both genetic and environmental factors play critical roles in the development of schizophrenia. Over the past decades, the roles of genetic factors have been attracting increased attentions in schizophrenia research. The neuregulin 1 (NRG1) gene has been identified as a candidate gene for schizophrenia in several genetics studies (Li et al., 2006; Liu et al., 2005; Petryshen et al., 2005; Stefansson et al., 2003; Williams et al., 2003; Yang et al., 2003) . NRG1 is a group of proteins that contains an epidermal growth factor (EGF)-like domain that signals by activating membrane-associated tyrosine kinases, especially the ErbB4 receptor kinases in the central nervous system (CNS) (Falls, 2003) . An association between the ErbB4 gene and schizophrenia has also been reported (Law et al., 2007; Nicodemus et al., 2006; Silberberg et al., 2006) . Additionally, schizophrenia is believed to be a neurodevelopmental disorder (Harrison, 1997) . A wide range of studies has shown that NRG1-induced stimulation of the ErbB4 receptor performs multiple biological functions in neurodevelopment, including radial glia formation and neuronal migration (Anton et al., 1997; Rio et al., 1997; Yau et al., 2003) , glial cell development, axon myelination and axon ensheathment (Calaora et al., 2001; Canoll et al., 1996; Michailov et al., 2004; Nave and Salzer, 2006; Schmucker et al., 2003; Taveggia et al., 2005) , axon guidance (BerminghamMcDonogh et al., 1996; Gerecke et al., 2004; Lopez-Bendito et al., 2006; Rieff et al., 1999) , dendritic development (Gerecke et al., 2004; Rieff and Corfas, 2006) , and the expression of several neurotransmitter receptors (Liu et al., 2001; Okada and Corfas, 2004; Ozaki et al., 1997; Rieff et al., 1999; Xie et al., 2004) . Several studies have revealed that animals with impaired NRG1-ErbB4 signalling displayed abnormal behaviours relevant to certain features of schizophrenia (Barros et al., 2009; Dejaegere et al., 2008; Rimer et al., 2005; Savonenko et al., 2008; Stefansson et al., 2002) .
In order to treat symptoms of schizophrenia, various antipsychotic drugs, including typical and atypical antipsychotics, are widely used in Abbreviations: 5-HT, serotonin; BA, Brodmann areas; BACE1, a transmembrane endopeptidase β-site APP-cleaving enzyme 1; CNS, central nervous system; CYT, C-terminal cytoplasmic tails; ErbB4, membrane-associated tyrosine kinases, ErbB4 receptor kinases; EGF, epidermal growth factor; Ig, immunoglobulin; GABA, γ-Aminobutyric acid; GPCRs, G-protein couple receptors; NMDA, N-methyl-D-aspartate; NRG1, neuregulin 1; PBLs, peripheral blood lymphocytes; PFC, prefrontal cortex; PPI, prepulse inhibition; PSD95, post synaptic density protein 95; SNP, single-nucleotide polymorphism; TACE, tumour necrosis factor-α converting enzyme; TMc, transmembrane domain. E-mail address: chao@uow.edu.au (C. Deng).
